Dark Pool•Event Sunday, October 12, 2025Analyzed

Sana Biotechnology

Bullish

Synthetic Biology & Intracellular mRNA Delivery

Summary

Sana Biotechnology raised $194.6M in a Regulation D private placement, first sale on 2025-10-12, in the synthetic biology and intracellular mRNA delivery sector. The filing lists Lockheed Martin Ventures and Bessemer Venture Partners as related persons, signaling deep-tech and defense-linked investor interest. This is a Form D initial notice, not an amendment, indicating fresh capital deployment.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Full Analysis

### Executive Summary Sana Biotechnology raised $194.6M in a Regulation D private placement, first sale on 2025-10-12, in the synthetic biology and intracellular mRNA delivery sector. The filing lists Lockheed Martin Ventures and Bessemer Venture Partners as related persons, signaling deep-tech and defense-linked investor interest. This is a Form D initial notice, not an amendment, indicating fresh capital deployment. ### Investor Edge Watch for subsequent Form D/A amendments to see if the round expands, and monitor Lockheed Martin for any public contract announcements related to intracellular delivery or synthetic biology platforms. ### Sector capital positioning This large raise in synthetic biology and mRNA delivery underscores sustained private capital flow into programmable biology and intracellular therapeutics, with defense crossover interest from Lockheed Martin Ventures. ### Convergence Signals No explicit public signals (patents, contracts, legislation) are mentioned in the filing. However, Lockheed Martin Ventures' involvement suggests potential defense or dual-use applications in mRNA delivery or synthetic biology. ### Key Takeaways - Sana Biotechnology raised $194.6M in a private placement, first sale October 2025. - Lockheed Martin Ventures and Bessemer Venture Partners are listed as related persons, indicating defense and venture capital interest. - The filing is a Form D initial notice, not an amendment, suggesting new capital rather than a modification. ### Risk Indicators & Flags No red flags: this is a standard Form D initial notice with no amendments. The sector is capital-intensive but the amount is large for a private placement; verify if the company has any regulatory or IP risks not disclosed in this filing. ### Verification & References Filing accession 0001702600-24-20079 on SEC EDGAR. Verify company name, capital raised ($194.6M), first sale date (2025-10-12), and related persons (Lockheed Martin Ventures, Bessemer Venture Partners) at https://www.sec.gov/cgi-bin/browse-edgar?company=Sana%20Biotechnology&type=D&action=getcompany.